These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 476637)

  • 1. Effect of tetrahydrouridine on the action of 1-beta-D-arabinofuranosylcytosine in synchronized cultures of normal rat kidney cells.
    Wan CW; Mak TW
    Cancer Res; 1979 Oct; 39(10):3981-5. PubMed ID: 476637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine.
    Riccardi R; Chabner B; Glaubiger DL; Wood J; Poplack DG
    Cancer Res; 1982 May; 42(5):1736-9. PubMed ID: 6896013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours.
    Kreis W; Chan K; Budman DR; Schulman P; Allen S; Weiselberg L; Lichtman S; Henderson V; Freeman J; Deere M
    Cancer Res; 1988 Mar; 48(5):1337-42. PubMed ID: 3342412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.
    Kreis W; Hession C; Soricelli A; Scully K
    Cancer Treat Rep; 1977 Oct; 61(7):1355-64. PubMed ID: 589601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
    Avramis VI; Powell W
    Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside.
    Wong PP; Currie VE; Mackey RW; Krakoff IH; Tan CT; Burchenal JH; Young CW
    Cancer Treat Rep; 1979 Aug; 63(8):1245-9. PubMed ID: 383291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
    Chandrasekaran B; Capizzi RL; Kute TE; Morgan T; Dimling J
    Cancer Res; 1989 Jun; 49(12):3259-66. PubMed ID: 2720678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man.
    Kreis W; Woodcock TM; Gordon CS; Krakoff IH
    Cancer Treat Rep; 1977 Oct; 61(7):1347-53. PubMed ID: 589600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics and mechanism of the 1-beta-D-arabinofuranosylcytosine-induced potentiation of cis-diamminedichloroplatinum(II) cytotoxicity.
    Vadi H; Drewinko B
    Cancer Res; 1986 Mar; 46(3):1105-9. PubMed ID: 3080232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deoxycytidine kinase and cytosine nucleoside deaminase activities in synchronized cultures of normal rat kidney cells.
    Wan CW; Mak TW
    Cancer Res; 1978 Sep; 38(9):2768-72. PubMed ID: 679182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased cytotoxicity of 1-beta-D-arabinofuranosylcytosine in 9L rat brain tumor cells pretreated with alpha-difluoromethylornithine in vitro.
    Oredsson SM; Gray JW; Deen DF; Marton LJ
    Cancer Res; 1983 Jun; 43(6):2541-4. PubMed ID: 6406046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of tetrahydrouridine on metabolism and transport of 1-beta-D-arabinofuranosylcytosine in human cells.
    Riva C; Barra Y; Carcassonne Y; Cano JP; Rustum Y
    Chemotherapy; 1992; 38(5):358-66. PubMed ID: 1286578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of 1-beta-D-arabinofuranosylcytosine on cell viability, DNA synthesis, and chromatid breakage in synchronized hamster fibrosarcoma cells.
    Jones PA; Baker MS; Benedict WF
    Cancer Res; 1976 Oct; 36(10):3789-97. PubMed ID: 986242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
    Bhalla K; Nayak R; Grant S
    Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro biochemical and cytotoxicity studies with 1-beta-D-arabinofuranosylcytosine and 5-azacytidine in combination.
    Momparler RL; Goodman J; Karon M
    Cancer Res; 1975 Oct; 35(10):2853-7. PubMed ID: 50882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
    Grant S; Bhalla K; McCrady C
    Leuk Res; 1991; 15(4):205-13. PubMed ID: 2030601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo studies on high-dose 1-beta-D-arabinofuranosylcytosine (HDara-C) and 1-beta-D-arabinofuranosyluracil (ara-U) with respect to pharmacokinetics, cell kinetics, and cytotoxicity in a rat myelocytic leukemia model (BNML).
    Colly LP; Willemze R; Honders W; vd Hoorn F; Edelbroek PM
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):49-54. PubMed ID: 3859932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of 5-trifluoromethyldeoxycytidine and tetrahydrouridine to circumvent catabolism and exploit high levels of cytidine deaminase in tumors to achieve DNA- and target-directed therapies.
    Mekras JA; Boothman DA; Greer SB
    Cancer Res; 1985 Nov; 45(11 Pt 1):5270-80. PubMed ID: 2932216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of tetrahydrouridine on the phosphorylation of 1-beta-D-arabinofuranosyl-cytosine (ara-C) by enzymes from solid tumors in vitro.
    Furner RL; Mellett LB; Herren TC
    J Pharmacol Exp Ther; 1975 Jul; 194(1):103-10. PubMed ID: 1057009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in human leukemia cells by deoxycytidine 5'-triphosphate.
    Liliemark JO; Plunkett W
    Cancer Res; 1986 Mar; 46(3):1079-83. PubMed ID: 3484676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.